Abstract
Idiopathic membranous nephropathy is a common cause of nephrotic syndrome in adults. The nephrotic syndrome due to idiopathic membranous nephropathy is often resistant to glucocorticosteroids and requires an alkylating agent such as chlorambucil or cyclophosphamide to induce remission. Recent studies illustrate that antibodies against the autoantigen M-type phospholipase A2 receptor contribute to a vast majority but not all cases of idiopathic membranous nephropathy. Herein, we report a patient with nephrotic syndrome due to membranous nephropathy that was resistant to 6 months of therapy with ramipril and high-dose glucocorticosteroids but responded to a single cycle of bortezomib infusion.
This is a preview of subscription content, log in via an institution to check access.
References
Ponticelli C, Glassock RJ (2013) Glomerular diseases: membranous nephropathy—a modern view. Clin J Am Soc Nephrol. doi:10.2215/CJN.04160413
Polanco N, Gutierrez E, Covarsi A et al (2010) Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21(4):697–704
Cattran DC, Pei Y, Greenwood CM et al (1997) Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 51:901–907
Kidney Disease Improving Global Outcomes (2012) KDIGO clinical practice guidelines for glomerulonephritis. Kidney Int 2:139–172
Beck LH, Bonegio RGB, Lambeau G et al (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361:11–21
Murtas C, Bruschi M, Candiano G et al (2012) Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol 7:1394–1400
Ponticelli C, Zucchelli P, Passerini P et al (1989) A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 320:8–13
Howman A, Chapman TL, Langdon MM et al (2013) Immunosuppression for progressive membranous nephropathy: a UK randomized controlled trial. Lancet 381:744–751
Shortt J, Oh DH, Opat SS (2013) ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med 368:90–92
Forslund T, Sikio A, Anttinen J (2007) IgA nephropathy in a patient with IgG lambda light-chain plasmacytoma: a rare coincidence. Nephrol Dial Transplant 22:2705–2708
Ruggenenti P, Cravedi P, Chianca A et al (2012) Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 23:1416–1425
Perry DK, Burns JM, Pollinger HS et al (2009) Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 9(1):201–209
Beck LH Jr, Fervenza FC, Beck DM et al (2011) Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22:1543–1550
Acknowledgments
This work was supported by Millennium Pharmaceuticals and (#UL1TR000457) from the Weill Cornell Medical College Clinical & Translational Science Center, New York, New York.
Conflict of interest
The authors declare no relevant financial interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hartono, C., Chung, M., Kuo, S.F. et al. Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy. J Nephrol 27, 103–106 (2014). https://doi.org/10.1007/s40620-013-0028-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40620-013-0028-x